These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24667717)

  • 1. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
    Morris RT; Joyrich RN; Naumann RW; Shah NP; Maurer AH; Strauss HW; Uszler JM; Symanowski JT; Ellis PR; Harb WA
    Ann Oncol; 2014 Apr; 25(4):852-858. PubMed ID: 24667717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
    Naumann RW; Coleman RL; Burger RA; Sausville EA; Kutarska E; Ghamande SA; Gabrail NY; Depasquale SE; Nowara E; Gilbert L; Gersh RH; Teneriello MG; Harb WA; Konstantinopoulos PA; Penson RT; Symanowski JT; Lovejoy CD; Leamon CP; Morgenstern DE; Messmann RA
    J Clin Oncol; 2013 Dec; 31(35):4400-6. PubMed ID: 24127448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The folate receptor as a rational therapeutic target for personalized cancer treatment.
    Assaraf YG; Leamon CP; Reddy JA
    Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.
    Maurer AH; Elsinga P; Fanti S; Nguyen B; Oyen WJ; Weber WA
    J Nucl Med; 2014 May; 55(5):701-4. PubMed ID: 24732155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
    Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
    Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
    Ambrosio AJ; Suzin D; Palmer EL; Penson RT
    Expert Rev Clin Pharmacol; 2014 Jul; 7(4):443-50. PubMed ID: 24742319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vintafolide: a novel targeted agent for epithelial ovarian cancer.
    Graybill WS; Coleman RL
    Future Oncol; 2014 Mar; 10(4):541-8. PubMed ID: 24754586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical translation of folate receptor-targeted therapeutics.
    Teng L; Xie J; Teng L; Lee RJ
    Expert Opin Drug Deliv; 2012 Aug; 9(8):901-8. PubMed ID: 22663189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults.
    Yamada Y; Nakatani H; Yanaihara H; Omote M
    Ann Nucl Med; 2015 Nov; 29(9):792-8. PubMed ID: 26238440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments.
    Ledermann JA; Canevari S; Thigpen T
    Ann Oncol; 2015 Oct; 26(10):2034-43. PubMed ID: 26063635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of functional folate receptors by human parathyroid cells.
    Weber CJ; Müller S; Safley SA; Gordon KB; Amancha P; Villinger F; Camp VM; Lipowska M; Sharma J; Müller C; Schibli R; Low PS; Leamon CP; Halkar RK
    Surgery; 2013 Dec; 154(6):1385-93; discussion 1393. PubMed ID: 24206618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung.
    Edelman MJ; Harb WA; Pal SE; Boccia RV; Kraut MJ; Bonomi P; Conley BA; Rogers JS; Messmann RA; Garon EB
    J Thorac Oncol; 2012 Oct; 7(10):1618-21. PubMed ID: 22982661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide.
    Serpe L; Gallicchio M; Canaparo R; Dosio F
    Pharmgenomics Pers Med; 2014; 7():31-42. PubMed ID: 24516337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
    Guertin AD; O'Neil J; Stoeck A; Reddy JA; Cristescu R; Haines BB; Hinton MC; Dorton R; Bloomfield A; Nelson M; Vetzel M; Lejnine S; Nebozhyn M; Zhang T; Loboda A; Picard KL; Schmidt EV; Dussault I; Leamon CP
    Mol Cancer Ther; 2016 Aug; 15(8):1998-2008. PubMed ID: 27256377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Preclinical Evaluation of Folate-NOTA-Al(18)F for PET Imaging of Folate-Receptor-Positive Tumors.
    Chen Q; Meng X; McQuade P; Rubins D; Lin SA; Zeng Z; Haley H; Miller P; González Trotter D; Low PS
    Mol Pharm; 2016 May; 13(5):1520-7. PubMed ID: 27054811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
    Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
    Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
    Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
    Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
    Lorusso PM; Edelman MJ; Bever SL; Forman KM; Pilat M; Quinn MF; Li J; Heath EI; Malburg LM; Klein PJ; Leamon CP; Messmann RA; Sausville EA
    J Clin Oncol; 2012 Nov; 30(32):4011-6. PubMed ID: 23032618
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.